|
Market Closed -
NYSE
01:34:22 19/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 102.61 USD | +0.37% |
|
-0.73% | -18.10% |
| 18/09 | Trinity Heart Experts First in the Quad Cities to Use New Afib Technology | CI |
| 17/09 | Abbott Laboratories Declares Quarterly Dividend, Payable on Nov. 16, 2026 | CI |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,41,365 | 1,91,427 | 1,91,088 | 1,96,184 | 2,17,859 | 1,76,897 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -18.8% | - | - |
| Enterprise Value (EV) 1 | 2,49,166 | 1,98,318 | 1,98,871 | 2,02,693 | 2,22,266 | 2,00,836 | 1,97,854 | 1,94,164 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -9.64% | -1.48% | -1.87% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 29x | 22.5x | 20x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.69x | 3.54x | 3.36x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.67x | 0.8x | 1.6x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.52x | 3.24x | 3.04x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4x | 3.63x | 3.33x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.5x | 13.7x | 12.2x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.1x | 15.2x | 13.6x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.6x | 22.2x | 20.2x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.76% | 4.51% | 4.94% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.51% | 2.68% | 2.83% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.53 | 4.553 | 5.106 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 72.8% | 60.2% | 56.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,204 | 54,528 | 58,247 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,989 | 14,491 | 15,854 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,319 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,303 | 7,978 | 8,906 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 102.23 | 102.23 | 102.23 |
| Nbr of stocks (in thousands) | 17,14,968 | 17,43,574 | 17,36,059 | 17,34,455 | 17,38,834 | 17,30,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.96x | 4x | 15.46x | 2.51% | 18TCr | |
| 19.63x | 3.58x | 12.79x | 3.04% | 12TCr | |
| 16.94x | 0.2x | 12.43x | 0.77% | 5.9TCr | |
| 34.95x | 3.39x | 11.6x | 2.16% | 4.94TCr | |
| 27.72x | 6.83x | 17.58x | 1.44% | 4.86TCr | |
| 35.25x | 6.2x | 19.46x | -.--% | 3.32TCr | |
| 41.47x | 1.23x | 11.35x | 0.23% | 2.82TCr | |
| 42.75x | 7.5x | 26.89x | 0.25% | 2.58TCr | |
| 50.01x | 6.74x | 21.68x | 0.42% | 2.19TCr | |
| 17.09x | 2.72x | 9.61x | 1.62% | 2.17TCr | |
| Average | 31.48x | 4.24x | 15.89x | 1.24% | 5.83TCr | |
| Weighted average by Cap. | 28.17x | 3.91x | 15.01x | 1.86% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
